PA
IMVT icon

Profund Advisors’s Immunovant IMVT Stock Holding History

Profund Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
36,510
-24,498
-40% -$746K 0.04% 280
2026
Q1 		$1.52M Buy
61,008
+11,932
+24% +$309K 0.06% 246
2025
Q4 		$1.25M Buy
49,076
+26,810
+120% +$598K 0.04% 297
2025
Q3 		$359K Sell
22,266
-170
-0.8% -$2.75K 0.01% 655
2025
Q2 		$359K Sell
22,436
-6,124
-21% -$92.6K 0.01% 596
2025
Q1 		$488K Buy
28,560
+5,850
+26% +$122K 0.02% 480
2024
Q4 		$563K Sell
22,710
-7,321
-24% -$208K 0.02% 456
2024
Q3 		$856K Buy
30,031
+3,891
+15% +$115K 0.03% 365
2024
Q2 		$690K Sell
26,140
-18,864
-42% -$537K 0.03% 398
2024
Q1 		$1.45M Buy
45,004
+7,544
+20% +$275K 0.06% 242
2023
Q4 		$1.58M Sell
37,460
-12,409
-25% -$457K 0.07% 233
2023
Q3 		$1.91M Buy
49,869
+4,115
+9% +$93K 0.11% 155
2023
Q2 		$868K Sell
45,754
-14,735
-24% -$275K 0.05% 347
2023
Q1 		$938K Buy
+60,489
New +$1.05M 0.06% 316

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Profund Advisors's IMVT Position: Q2 2026 in Review

Profund Advisors reduced its Immunovant (IMVT) stake by 40% in Q2 2026, selling an estimated $746K and leaving 36,510 shares worth $1.41M. The position accounts for 0.04% of the portfolio, ranked #280.

Profund Advisors first reported a position in IMVT in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.91M in Q3 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Profund Advisors held 36,510 shares of Immunovant worth $1.41M as of Q2 2026.
  • Profund Advisors sold 24,498 Immunovant shares in Q2 2026, an estimated $746K.
  • Immunovant made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #280 holding.
  • Profund Advisors first reported a position in Immunovant in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Immunovant position peaked at $1.91M in Q3 2023.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.